Not Tagged
Not Tagged
['solid tumor']
our mdm2-p53 antagonist showed a manageable safety profile and encouraging signs of efficacy in this publication from an open-label, first-in-human, phase ia/ib study in people with advanced solid tumors and mdm2 amplification. further investigations are ongoing. #asco23 
Global Head of Cancer Research @Boehringer. Focus on improving the lives of cancer patients.